LifeSci Advisors Initiates Coverage of BioAmber Inc (NYSE: BIOA)

LifeSci Advisors Initiates Coverage of BioAmber Inc (NYSE: BIOA) 
With a Fully-Funded Manufacturing Facility Under Construction,
BioAmber Has the Pieces in Place to Become a Leading Renewable
Chemicals Company; Available for Download at 
NEW YORK, NY -- (Marketwired) -- 10/08/13 --  LifeSci Advisors, LLC,
a leading provider of investment research and investor relations
services in the life sciences sector, today announced that it has
initiated coverage of BioAmber Inc. (NYSE: BIOA), an industrial
biotechnology company that combines advanced fermentation technology
and conventional chemistry to manufacture bio-based chemicals.
BioAmber is currently building manufacturing capacity for the
production of bio-based succinic acid, a building block chemical. The
Company has a technology platform that combines industrial
biotechnology with chemical catalysis for the conversion of renewable
feedstocks into sustainable chemicals. The goal is to replace
petroleum-based chemicals with renewable equivalents in a
cost-competitive manner. 
"BioAmber has all of the pieces in place needed to become a
successful commercial scale chemical manufacturer and leader in the
green chemical industry," said Andrew I. McDonald, Ph.D., Founding
Partner at LifeSci Advisors. "They have already demonstrated large
scale production of succinic acid at their demonstration plant, and
the fully funded plant they are building in Sarnia, Ontario will be
mechanically operational by the end of 2014." 
BioAmber has a plan in place to produce world-scale quantities of
bio-based succinic acid, including collaborations with key industry
partners, an experienced management team, and the necessary capital
to execute the plan. Experience gained at BioAmber's demonstration
plant, believed to be one of the largest bio-based chemical
production facilities, is being used to inform the ongoing
construction of a new facility in Sarnia, Ontario. The new plant that
will be able to produce 30,000 metric tons of bio-SA per year, with
potential to increase capacity to 50,000 metric tons. This new
facility is fully funded from a combination of sources including
BioAmber's partner Mitsui & Co., confirmed government grants and
loans, an established loan, and proceeds of the recent IPO. BioAmber
already has contracts in place to sell the final product and is also
working with partners to find further uses for bio-SA. 
In a 50 page Initiation Report by LifeSci Advisors, we explain
BioAmber's technology and business plan, including details of the
ongoing construction of the commercial scale manufacturing plant in
Sarnia, Ontario, the Company's yeast fermentation technology, and
efforts to develop new products and markets for succinic acid and its
derivatives. We also explore the industry landscape for industrial
biotechnology and explain how BioAmber's peers, by failing to perform
to expectations, have made investment in the sector difficult. This
has, in turn, created a potential opportunity in BioAmber. 
Dr. McDonald's full Initiation Report is available to download at no
cost at the LifeSci Advisors website, In
addition to this Initiation Report, LifeSci Advisors will also
provide ongoing coverage and event-based research updates on the
Company as developments occur. 
The LifeSci Advisors research team is led by Dr. Andrew I. McDonald,
an industry veteran with more than 15 years of healthcare industry
experience. Prior to co-founding LSA, Dr. McDonald was the Senior
Biotechnology Analyst at Great Point Partners, a leading health care
investment firm with over $500 million under management. Before Great
Point, he was Co-Head of Healthcare Research and Lead Biotechnology
Analyst at ThinkEquity Partners, a boutique investment banking firm
focused on growth companies. Dr. McDonald holds a Ph.D. in organic
chemistry from the University of California, Irvine, and, earlier in
his career, worked as a medicinal chemist at both Pfizer and
About LifeSci Advisors: 
LifeSci Advisors (LSA) is a leading research firm and communications
consultancy dedicated to the life sciences industry. The firm
provides strategic counsel, customized marketing communications,
comprehensive research reports and investor relations services to
companies that specialize in the discovery, development and
commercialization of drugs, drug delivery systems, medical devices
and diagnostics. To learn more about LSA, visit the company's
Important Disclosures: 
The research report described in this press release is not intended
as an offering, recommendation, or a solicitation of an offer to buy
or sell securities. The securities discussed in LSA research reports
may be unsuitable for some investors depending on their specific
investment objectives, financial status, risk profile, or particular
needs. Investors should consider LSA reports as only a single factor
in making their investment decisions and should not rely solely on
these reports in evaluating whether or not to buy or sell the
securities of the subject company. LifeSci Advisors has been
compensated by the company that is the subject of the report
described and future research reports, investor relations services,
and general consulting services. Please read each report's full
disclosures and analyst background on the LSA website,, before investing. LifeSci Advisors is not a
registered investment adviser or broker-dealer.  
Forward-looking statements: 
This press release contains forward-looking statements subject to
risks and uncertainties that could cause actual results to differ
materially from those projected. These forward-looking statements
represent LSA's judgment as of the date of this release. LifeSci
Advisors disclaims, however, any intent or obligation to update these
forward-looking statements. 
Media Contact:
Michael Rice
Phone: (646) 597-6979
BioAmber Contact:
Mike Hartmann 
Executive VP
Phone: 514-844-8000 ext. 120
Press spacebar to pause and continue. Press esc to stop.